Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

CONMED Corporation

CNMD

Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.

Last trade $48.66
Day change -$0.69 (-1.40%)
Day range $48.58 – $50.43
Volume 123,856
Market cap $1.47B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.47B
Price / earnings
20.03×
Price / book
1.39×
Price / sales
1.07×
EV / sales
1.63×
EV / EBITDA
13.43×

Profitability

Earnings per share
$2.46
Return on assets
3.19%
Return on equity
6.93%
Dividend yield
0.42%

Liquidity and leverage

Debt / equity
0.77×
Current ratio
1.49×
Quick ratio
0.7×
Cash ratio
0.1×

Cash flow

Price / cash flow
10.05×
Price / free cash flow
11.08×
Free cash flow
$132.69M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CNMD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$335.56M$343.49M$317.05M$373.2M$337.93M$342.35M$321.26M$345.94M
Cost of revenue$146.41M$146.03M$133.6M$154.91M$171.81M$154.03M$143.5M$147.6M
Gross profit$189.15M$197.46M$183.45M$218.29M$166.12M$188.32M$177.75M$198.34M
Selling, general and administrative$136.42M$145.55M$141.7M$166.76M$140.34M$136.02M$148.85M$132.67M
Research and development$15.59M$15.5M$16.33M$14.9M$13.9M$14.14M$12.95M$13.18M
Total operating expenses$152M$161.05M$158.03M$181.66M$154.24M$150.16M$161.79M$145.85M
Operating income$37.14M$36.41M$25.42M$36.62M$11.88M$38.16M$15.96M$52.5M
Interest expense-$11.14M-$7.88M-$7.06M-$7.37M-$7.61M-$7.82M-$8.29M-$8.86M
Income before taxes$26.01M$31.35M$18.36M$29.25M$4.27M$29.92M$7.67M$43.64M
Income taxes$6.21M$8.28M$4.53M$12.51M$1.41M$8.5M$1.64M$9.89M
Net income$19.8M$23.07M$13.83M$16.74M$2.86M$21.42M$6.04M$33.76M
Net income attributable to common shareholders$19.8M$23.07M$13.83M$16.74M$2.86M$21.42M$6.04M$33.76M
EBITDA$11.5M$55.45M$44.25M$55.47M-$11.87M$56.73M$34.21M$70.51M
Basic earnings per share$0.66$0.77$0.45$0.54$0.09$0.69$0.19$1.09
Diluted earnings per share$0.66$0.77$0.45$0.53$0.09$0.69$0.19$1.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED (CNMD) is positioned for growth through its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, supported by expanding surgical adoption and favorable legislation. However, the company faces near-term challenges including U.S. orthopedic weakness, tariff pressures, and OEM business volatility. 2026 EPS estimates were raised to $4.58 per share despite headwinds.

Zacks Investment Research

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed reported Q3 2026 earnings of $1.04 per share, beating consensus estimates of $1.00, but revenues of $335.56 million missed expectations by 0.37%. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Conmed has outperformed the S&P 500 by 3.5% year-to-date, though its industry ranks in the bottom 38% of Zacks industries.

Zacks Investment Research

Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings

Conmed reported Q3 2026 revenue of $335.56 million, down 0.7% year-over-year, slightly missing consensus estimates. EPS of $1.04 beat expectations of $1.00. The company showed mixed performance across segments, with international revenue up 13.2% but domestic revenue declining 11%. The stock has a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Is Cardinal Health Building a New Tech-Enabled Healthcare Platform?

Cardinal Health is leveraging technology investments across distribution, specialty services, and logistics to operate as a tech-enabled healthcare platform. The company integrated Sonexus into its Nuclear business web-ordering platform for end-to-end digital workflows, achieved a 99% fill rate, and plans $700 million in fiscal 2027 capital spending. Peers CONMED and Align Technology are similarly expanding their technology-driven healthcare solutions.

GlobeNewswire Inc.

Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - Analysis by Product, Surgery, End User and Region

The global electrosurgery market is projected to grow from $8.01 billion in 2025 to $11.59 billion by 2031, with a CAGR of 6.4%. Growth is driven by increasing surgical volumes, rising chronic disease prevalence, and adoption of minimally invasive procedures. However, challenges include procedural risks, regulatory constraints, and surgeon shortages. Ambulatory surgical centers are expanding their role, while the United States leads North American growth.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 15, 2025$0.20Oct 3, 2025recurring
Jun 13, 2025$0.20Jul 3, 2025recurring
Mar 14, 2025$0.20Apr 4, 2025recurring
Dec 20, 2024$0.20Jan 3, 2025recurring
Sep 16, 2024$0.20Oct 4, 2024recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.